<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403260</url>
  </required_header>
  <id_info>
    <org_study_id>SP-C-004-06</org_study_id>
    <nct_id>NCT00403260</nct_id>
  </id_info>
  <brief_title>Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients</brief_title>
  <official_title>A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children &amp; Adult Patients With Acute Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shin Poong Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <brief_summary>
    <textblock>
      The primary objective of this phase III clinical study is to compare the efficacy and safety&#xD;
      of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of the&#xD;
      combination of mefloquine plus artesunate (MQ + AS) in children and adults with uncomplicated&#xD;
      P falciparum malaria in South East Asia, India and Africa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, comparative, randomised, open-label, parallel-group, non-inferiority&#xD;
      study comparing the efficacy and safety of a fixed combination of PA to a loose combination&#xD;
      of MQ + AS for patients with acute, symptomatic, uncomplicated P. falciparum malaria. The&#xD;
      study population will include 1271 patients, comprising male and female children (≥20 kg body&#xD;
      weight) and adults, recruited from study sites in South East Asia, India and Africa. Patients&#xD;
      will be randomised in a 2:1 ratio to receive either oral PA (180:60mg tablets) or MQ (250mg&#xD;
      tablets) plus AS (100mg tablets) once a day for 3 consecutive days (Days 0, 1, and 2). The&#xD;
      study drug will be administered by a Third-Party Investigator unblinded to the study&#xD;
      treatment, while the Investigator remains blinded.&#xD;
&#xD;
      Patients will be confined to the to the study facility for ≥4 days (Days 0, 1, 2, and 3) and&#xD;
      remain near the study site for ≥7 days, or once fever and parasite clearance has been&#xD;
      confirmed for ≥24 hours - whichever occurs later.&#xD;
&#xD;
      The primary efficacy end point for the study is the proportion of patients with PCR-corrected&#xD;
      adequate clinical and parasitological response (ACPR) on Day 28. Scheduled follow-up visits&#xD;
      will continue until completion of the study at Day 42. In the case of adverse events reported&#xD;
      and unresolved at Day 42, patients will be followed up for a further 30 days, or until&#xD;
      resolution of the event.&#xD;
&#xD;
      The primary efficacy end point for the study is the proportion of subjects with PCR-corrected&#xD;
      adequate clinical and parasitological response (ACPR) on Day 28 (defined as the absence of&#xD;
      parasitaemia without the subject's meeting any of the criteria of early treatment failure,&#xD;
      late clinical failure, or late parasitological failure). Scheduled follow-up visits will&#xD;
      continue until completion of the study at Day 42. In the case of adverse events reported and&#xD;
      unresolved at Day 42, patients will be followed up for a further 30 days, or until resolution&#xD;
      of the event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR-corrected ACPR on Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crude ACPR on Days 14 and 28</measure>
    <time_frame>Days 14 and 28</time_frame>
    <description>Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time</measure>
    <time_frame>Thick blood films were examined every 8 hours until ≥72 hours or until 2 consecutive negative readings occurred 7 to 25 hours apart, and on Days 3, 7, 14, 21, 28, 35, and 42 (or any other day if the subject returned).</time_frame>
    <description>Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time</measure>
    <time_frame>Every 8 hours over ≥72 hours following first study drug administration or temperature normalisation for ≥2 readings between 7 and 25 hours apart, then at each visit.</time_frame>
    <description>Fever clearance time was defined as the time from first dosing to first normal reading of temperature (&lt;37.5°C taken axillary or tympanic; &lt;38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance at Day 1, 2 and 3</measure>
    <time_frame>Days 1, 2 and 3</time_frame>
    <description>Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance at Day 1, 2 and 3</measure>
    <time_frame>Days 1, 2 and 3</time_frame>
    <description>Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (&lt;37.5°C axillary/tympanic or &lt;38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Clinically Significant Laboratory Results</measure>
    <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
    <description>Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1271</enrollment>
  <condition>Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Pyronaridine - artesunate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mefloquine plus artesunate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine - artesunate</intervention_name>
    <description>once a day for 3 days</description>
    <arm_group_label>Pyronaridine - artesunate</arm_group_label>
    <other_name>Pyramax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefloquine plus artesunate</intervention_name>
    <description>once a day for 3 days</description>
    <arm_group_label>Mefloquine plus artesunate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients between the ages of 3 and 60 years, inclusive.&#xD;
&#xD;
          -  Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.&#xD;
&#xD;
          -  Presence of acute uncomplicated P. falciparum mono-infection confirmed by:&#xD;
&#xD;
               1. Fever, as defined by axillary/tympanic temperature ≥37.5°C or oral/rectal&#xD;
                  temperature ≥38°C, or documented history of fever in the previous 24 hours and,&#xD;
&#xD;
               2. Positive microscopy of P. falciparum with parasite density between 1,000 and&#xD;
                  100,000 asexual parasite count/µl of blood&#xD;
&#xD;
          -  Written informed consent provided by patient and/or parent/guardian/spouse.&#xD;
&#xD;
          -  Ability to swallow oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with signs and symptoms of severe/complicated malaria requiring parenteral&#xD;
             treatment according to the World Health Organization Criteria 2000.&#xD;
&#xD;
          -  Mixed Plasmodium infection.&#xD;
&#xD;
          -  Severe vomiting or severe diarrhoea.&#xD;
&#xD;
          -  Known history or evidence of clinically significant disorders.&#xD;
&#xD;
          -  Presence of significant anaemia, as defined by Hb &lt;8 g/dL.&#xD;
&#xD;
          -  Presence of febrile conditions caused by diseases other than malaria.&#xD;
&#xD;
          -  Known history of hypersensitivity, allergic or adverse reactions to pyronaridine,&#xD;
             mefloquine or artesunate or other artemisinins.&#xD;
&#xD;
          -  Use of any other antimalarial agent within 2 weeks prior to start of the study as&#xD;
             evidenced by positive urine test.&#xD;
&#xD;
          -  Female patients of child-bearing potential must be neither pregnant (as demonstrated&#xD;
             by a negative pregnancy test) nor lactating, and must be willing to take measures to&#xD;
             not become pregnant during the study period.&#xD;
&#xD;
          -  Presence of significant renal or hepatic impairment.&#xD;
&#xD;
          -  Receipt of an investigational drug within the past 4 weeks.&#xD;
&#xD;
          -  Known active Hepatitis A IgM, Hepatitis B surface antigen or Hepatitis C antibody.&#xD;
&#xD;
          -  Known seropositive HIV antibody.&#xD;
&#xD;
          -  Previous participation in any clinical study with PA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Borghini-Fuhrer, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medicines for Malaria Venture</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RAOTAP2/Centre Muraz</name>
      <address>
        <city>Bobo Dioulasso</city>
        <state>Houet Province</state>
        <zip>01 BP390</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pailin Referral Hospital</name>
      <address>
        <city>Pailin</city>
        <state>Pailin Province</state>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wentlock District Hospital</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagamoyo Research and Training Centre of Ifakara Health Institute</name>
      <address>
        <city>Bagamoyo</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MaeLamad District Hospital</name>
      <address>
        <city>Mae Ramat</city>
        <state>Tak Province</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MaeSod General Hospital</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak Province</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIMPE</name>
      <address>
        <city>Hanoi</city>
        <state>Commune Xy</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choray Hospital, Dak O</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Cambodia</country>
    <country>Côte D'Ivoire</country>
    <country>India</country>
    <country>Tanzania</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>http://www.mmv.org</url>
    <description>Medicines for Malaria Venture</description>
  </link>
  <results_reference>
    <citation>Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, Pénali LK, Valecha N, Tien NT, Abdulla S, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L; Pyronaridine-Artesunate Study Team. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med. 2012 Apr 5;366(14):1298-309. doi: 10.1056/NEJMoa1007125.</citation>
    <PMID>22475593</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 22, 2006</study_first_submitted>
  <study_first_submitted_qc>November 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2006</study_first_posted>
  <results_first_submitted>August 20, 2021</results_first_submitted>
  <results_first_submitted_qc>August 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2021</results_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>antimalarial</keyword>
  <keyword>P falciparum</keyword>
  <keyword>pyronaridine</keyword>
  <keyword>artesunate</keyword>
  <keyword>artemisinin based combination therapy (ACT)</keyword>
  <keyword>pyronaridine artesunate (Pyramax)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Mefloquine</mesh_term>
    <mesh_term>Pyronaridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pyronaridine - Artesunate</title>
          <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
        </group>
        <group group_id="P2">
          <title>Mefloquine Plus Artesunate</title>
          <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="848">Patients randomized and treated.</participants>
                <participants group_id="P2" count="423">Patients randomized and treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="723"/>
                <participants group_id="P2" count="357"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Re-appearance of P. falciparum</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>P. vivax infection</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mixed infection with P. vivax</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mixed infection with P. falciparum</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>P. vivax infection at screening</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>P. ovale infection</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Gametocyte re-appearance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn from study accidentally</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population, consisted of all randomized subjects who received any amount of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Pyronaridine - Artesunate</title>
          <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
        </group>
        <group group_id="B2">
          <title>Mefloquine Plus Artesunate</title>
          <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="848"/>
            <count group_id="B2" value="423"/>
            <count group_id="B3" value="1271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="11.67"/>
                    <measurement group_id="B2" value="25.4" spread="12.54"/>
                    <measurement group_id="B3" value="25.1" spread="11.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="4" upper_limit="60"/>
                    <measurement group_id="B2" value="23.0" lower_limit="5" upper_limit="59"/>
                    <measurement group_id="B3" value="23.0" lower_limit="4" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="307"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="634"/>
                    <measurement group_id="B2" value="330"/>
                    <measurement group_id="B3" value="964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="689"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="1033"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Vietnam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burkina Faso</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cambodia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Côte D'Ivoire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28</title>
        <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
        <time_frame>Day 28</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28</title>
          <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.</description>
          <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="749"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="98.3" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.1" lower_limit="96.1" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: The PCR-corrected ACPR response rate at Day 28 for the PA group is inferior to the PCR-corrected ACPR response rate at Day 28 for the comparator group (MQ + AS) by more than 5%.&#xD;
Was tested versus the alternative:&#xD;
Alternative hypothesis: the PCR-corrected ACPR response rate at Day 28 for the PA group is not inferior to the PCR-corrected ACPR response rate at Day 28 for the comparator group (MQ + AS) by more than -5%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>The primary efficacy analysis tested the non-inferiority of the PA group compared to the comparator group with regard to the PCR-corrected ACPR response rate at Day 28 using the 2-sided 95% confidence interval (CI) (Newcombe-Wilson score method without continuity correction). Non-inferiority of PA to MQ + AS was concluded if the lower limit of the CI for the difference was &gt;-5%.</non_inferiority_desc>
            <p_value>0.106</p_value>
            <p_value_desc>If non-inferiority of PA was demonstrated, the p-value associated with a superiority test is calculated based on a 2-sided Chi-square test. If the calculated p-value is &lt;5%, then the superiority of PA compared to MQ+AS was statistically demonstrated.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>ACPR percent difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR-corrected ACPR on Day 14</title>
        <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
        <time_frame>Day 14</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-corrected ACPR on Day 14</title>
          <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
          <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="749"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crude ACPR on Days 14 and 28</title>
        <description>Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
        <time_frame>Days 14 and 28</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>Crude ACPR on Days 14 and 28</title>
          <description>Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
          <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="749"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cure rate (%) on Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="99.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.5" lower_limit="98.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cure rate (%) on Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="97.6" upper_limit="99.4"/>
                    <measurement group_id="O2" value="96.7" lower_limit="94.4" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time</title>
        <description>Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
        <time_frame>Thick blood films were examined every 8 hours until ≥72 hours or until 2 consecutive negative readings occurred 7 to 25 hours apart, and on Days 3, 7, 14, 21, 28, 35, and 42 (or any other day if the subject returned).</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time</title>
          <description>Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
          <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="749"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="31.4" upper_limit="31.8"/>
                    <measurement group_id="O2" value="32.0" lower_limit="31.8" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance Time</title>
        <description>Fever clearance time was defined as the time from first dosing to first normal reading of temperature (&lt;37.5°C taken axillary or tympanic; &lt;38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.</description>
        <time_frame>Every 8 hours over ≥72 hours following first study drug administration or temperature normalisation for ≥2 readings between 7 and 25 hours apart, then at each visit.</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance Time</title>
          <description>Fever clearance time was defined as the time from first dosing to first normal reading of temperature (&lt;37.5°C taken axillary or tympanic; &lt;38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.</description>
          <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="627"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="15.7" upper_limit="16.0"/>
                    <measurement group_id="O2" value="16.0" lower_limit="15.7" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance at Day 1, 2 and 3</title>
        <description>Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
        <time_frame>Days 1, 2 and 3</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance at Day 1, 2 and 3</title>
          <description>Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.</description>
          <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="749"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance rate (%) at Day 1 (24h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="35.1" upper_limit="42.0"/>
                    <measurement group_id="O2" value="31.6" lower_limit="27.1" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 2 (48h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" lower_limit="81.1" upper_limit="86.4"/>
                    <measurement group_id="O2" value="79.8" lower_limit="75.6" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 3 (48h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" lower_limit="89.3" upper_limit="93.3"/>
                    <measurement group_id="O2" value="90.5" lower_limit="87.2" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance at Day 1, 2 and 3</title>
        <description>Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (&lt;37.5°C axillary/tympanic or &lt;38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing.</description>
        <time_frame>Days 1, 2 and 3</time_frame>
        <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance at Day 1, 2 and 3</title>
          <description>Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (&lt;37.5°C axillary/tympanic or &lt;38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing.</description>
          <population>Efficacy evaluable population subjects completed a full course of study med., did not miss a dose, did not use a concomitant med. that may have interfered with the treatment outcome up to D14, did not have a concomitant disease which may have interfered with the classification of the treatment outcome, and did not have major protocol deviations.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="627"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance rate (%) at Day 1 (24h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="75.2" upper_limit="81.6"/>
                    <measurement group_id="O2" value="78.9" lower_limit="74.2" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 2 (48h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="94.1" upper_limit="97.2"/>
                    <measurement group_id="O2" value="96.2" lower_limit="93.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 3 (72h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="98.2" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.4" lower_limit="96.5" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events and Clinically Significant Laboratory Results</title>
        <description>Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities</description>
        <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
        <population>The safety population consisted of all randomised subjects who received any amount of study medication; subjects were analysed as treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyronaridine - Artesunate</title>
            <description>Pyronaridine - artesunate (180:60mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
          <group group_id="O2">
            <title>Mefloquine Plus Artesunate</title>
            <description>Mefloquine (250mg) plus artesunate (100mg) once a day for 3 days. Posology was based on body weight ranges.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events and Clinically Significant Laboratory Results</title>
          <description>Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities</description>
          <population>The safety population consisted of all randomised subjects who received any amount of study medication; subjects were analysed as treated.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="848"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nr subj. with ≥1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 treatment-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 treatment-related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 severe or life threatenining AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj with ≥1 AE leading to drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 AE leading to study withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
      <desc>An AE was defined as any unfavorable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pyronaridine - Artesunate</title>
          <description>Pyronaridine artesunate (180:60mg)&#xD;
Pyronaridine artesunate: once a day for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Mefloquine Plus Artesunate</title>
          <description>Mefloquine (250mg) plus artesunate (100mg)&#xD;
Mefloquine plus artesunate: once a day for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="848"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia haemolytic autoimmune</sub_title>
                <description>Transient auto immune hemolytic anemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cholera</sub_title>
                <description>Cholera Inaba</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <description>Tonic clonic seizure. Treatment-related SAE.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>Seizure. Treatment related SAE.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="389" subjects_at_risk="848"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="848"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Basophilia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="848"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="848"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="848"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="848"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="848"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="848"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="848"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="848"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="848"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="848"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="848"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="848"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="848"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="848"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="848"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="39" subjects_at_risk="848"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="53" subjects_at_risk="848"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="848"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="423"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="120" subjects_affected="101" subjects_at_risk="848"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="848"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="848"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="423"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Duparc, MD</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>+41 22 555 0300</phone>
      <email>duparcs@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

